Cayuga Biotech is a clinical-stage biopharmaceutical company developing novel biomimetic therapies to address life-threatening hemorrhage. Leveraging inorganic polyphosphate, the company's first-in-class therapeutics harness the body's innate ability to stop bleeding, targeting noncompressible hemorrhage, coagulation dysfunction, and bleeding disorders. With over 3.5 million annual treatment opportunities, Cayuga addresses a $25B market.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
